CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 67 enrolled
Drug / intervention
SHR1316 +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04562337
NCT04562337Phase 2Active
CompareCT.gov

SHR-1316 Plus Chemotherapy and Sequential Thoracic Radiotherapy as First-line Therapy for Extensive-stage Small-Cell Lung Cancer (ES-SCLC): a Phase II Trial

Shandong Cancer Hospital and Institute·interventional·Posted Sep 24, 2020·Updated Jul 3, 2024

In Brief

A Phase 2 clinical trial evaluating SHR1316, Carboplatin, and 3 other interventions for Extensive-stage Small Cell Lung Cancer. Active but no longer recruiting, targeting 67 participants across 1 site.

Detailed Summary

This study is a one arm, open, single center phase II study. The main purpose of this study was to evaluate the tolerance and preliminary efficacy of SHR1316 combined with chest radiotherapy after induction therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsExtensive-stage Small Cell Lung Cancer
CountriesChina
Collaborators--

Timeline

Phase 2ActiveOverdue
202120222023202420252026
First PostedSep 24, 2020
Enrollment StartOct 1, 2020
Primary CompletionOct 1, 2024
TodayJul 1, 2026
Enrollment to primary: 4 yearsPosted 5.8 years ago

Interventions

SHR1316drug

Anti-PD-L1 antibody

Carboplatindrug

Carboplatin intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).

Etoposidedrug

Etoposide intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).

Radiation therapyradiation

Thoracic radiation therapy ,TRT

Cisplatindrug

Cisplatin intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).